Merck & Co., Inc. Q4 Earnings Call Highlights [Yahoo! Finance]
Merck & Company, Inc. (new) (MRK)
Last merck & company, inc. (new) earnings: 4/28 06:45 am
Check Earnings Report
US:NYSE Investor Relations:
investors.merck.com/home/default.aspx
Company Research
Source: Yahoo! Finance
For 2026 Merck guided non-GAAP revenue of $65.5–67.0 billion (1–3% growth) and non-GAAP EPS $5.00–5.15, but the outlook includes a one-time $9 billion Cidara charge that cuts reported EPS (management says the EPS midpoint would be about $9.03 excluding the upfront Cidara impact). Pipeline and regulatory progress includes positive phase III results for the oral PCSK9 candidate Enlicitide , advancement of MK-1406 (long-acting influenza prevention) with global ANCHOR enrollment activity, promising HIV two-drug weekly regimen data, and multiple oncology approvals/updates for Keytruda and related formulations. Interested in Merck & Co., Inc.? Here are five stocks we like better. 3 “Forever Stocks” to Hold When the Market Won't Sit Still Merck & Co., Inc. (NYSE:MRK) reported fourth-quarter 2025 revenue of $16.4 billion, up 5% year over year (4% excluding foreign exchange), as continued growth in oncology and animal health helped offset a sharp decline in Gardasil sales driven by we
Show less
Read more
Impact Snapshot
Event Time:
MRK
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MRK alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MRK alerts
High impacting Merck & Company, Inc. (new) news events
Weekly update
A roundup of the hottest topics
MRK
News
- ????????:2032????66?5000??????????????(CAGR)8.1%??? [CNET News]CNET News
- Merck veteran Perlmutter-led Eikon ?Therapeutics valued at $860 million in Nasdaq debut [Yahoo! Finance Canada]Yahoo! Finance Canada
- Merck Announces Health Canada Approval of ENFLONSIA® for the prevention of RSV in newborns and infants [Globe and Mail, The (Toronto, Canada)]Globe and Mail, The
- Perlmutter-backed Eikon Therapeutics raises $381.2 million in IPO [Yahoo! Finance]Yahoo! Finance
- Jim Cramer on Merck & Co.: “This Is One of My Favorite Pharmaceutical Stocks” [Yahoo! Finance]Yahoo! Finance
MRK
Earnings
- 2/3/26 - Beat
MRK
Sec Filings
- 2/5/26 - Form 144
- 2/4/26 - Form 144
- 2/4/26 - Form 144
- MRK's page on the SEC website